Join
Live feed
·
PRReleasevia Quantisnow
Stoke Therapeutics Inc. logo

Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
STOK· Stoke Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.) and more on Quantisnow.